hGears AG (FRA:HGEA)

Inozyme Pharma Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-21.17	-13.79	-0.84	2.35	6.71
Depreciation & Amortization	11.24	11.21	10.72	9.89	10
Other Amortization	0.25	0.59	0.56	0.53	0.55
Asset Writedown & Restructuring Costs	-	1.31	-	0.21	-
Other Operating Activities	2.96	1.68	-1.44	-0.93	-0.49
Change in Accounts Receivable	3.06	1.54	-0.24	0.02	1.36
Change in Inventory	3.43	0.21	-2.66	-2.89	1.72
Change in Other Net Operating Assets	-4.64	1.35	1.32	0.97	-2.58
Operating Cash Flow	-4.86	4.11	7.42	10.15	17.27
Operating Cash Flow Growth	-	-44.67%	-26.88%	-41.23%	37.96%
Capital Expenditures	-	-	-13.1	-14.19	-8.03
Sale of Property, Plant & Equipment	0.81	0.6	-	0.29	-
Investment in Securities	-1.45	-8.23	-	-	-
Investing Cash Flow	-0.64	-8.1	-14.1	-13.9	-8.03
Long-Term Debt Issued	24.66	5.07	20.13	0.13	16.34
Long-Term Debt Repaid	-28.8	-10.5	-24.32	-32.08	-19.73
Net Debt Issued (Repaid)	-4.14	-5.43	-4.19	-31.94	-3.4
Issuance of Common Stock	-	-	-	62.4	-
Other Financing Activities	-	-	-0.01	-3.27	-
Financing Cash Flow	-4.14	-5.43	-4.2	27.19	-3.4
Foreign Exchange Rate Adjustments	0.17	-0.25	-0.09	0.38	-0.11
Miscellaneous Cash Flow Adjustments	0	0	-	-	-
Net Cash Flow	-9.47	-9.68	-10.97	23.81	5.73
Free Cash Flow	-4.86	4.11	-5.68	-4.04	9.24
Free Cash Flow Margin	-5.08%	3.65%	-4.16%	-2.99%	7.31%
Free Cash Flow Per Share	-0.47	0.40	-0.55	-0.58	147.84
Cash Interest Paid	2.5	1.89	1.22	6.2	2.63
Cash Income Tax Paid	-0.18	-0.53	2.36	0.57	0.59
Levered Free Cash Flow	4.57	9.88	-5.3	-1.61	7.17
Unlevered Free Cash Flow	6.31	11.31	-4.44	0.7	8.99
Change in Net Working Capital	-2.95	-3.43	3.19	1.64	-0.83

Source: S&P Global Market Intelligence. Standard template. Financial Sources.